HUP0300548A2 - Poliol-ifn-béta konjugátumok - Google Patents

Poliol-ifn-béta konjugátumok

Info

Publication number
HUP0300548A2
HUP0300548A2 HU0300548A HUP0300548A HUP0300548A2 HU P0300548 A2 HUP0300548 A2 HU P0300548A2 HU 0300548 A HU0300548 A HU 0300548A HU P0300548 A HUP0300548 A HU P0300548A HU P0300548 A2 HUP0300548 A2 HU P0300548A2
Authority
HU
Hungary
Prior art keywords
peg
polyol
residue
interferon
polypeptide
Prior art date
Application number
HU0300548A
Other languages
English (en)
Inventor
Nabil El Tayar
Milton Harris
Michael J. Roberts
Wayne Sawlivich
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of HUP0300548A2 publication Critical patent/HUP0300548A2/hu
Publication of HUP0300548A3 publication Critical patent/HUP0300548A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány poliol-interferon-b konjugátumokra vonatkozik, amelyekbenegy poliolmaradék kovalensen kapcsolódik a humán interferon-b Cys17-hez. A fenti poliol-interferon-b konjugátumot úgy állítják elő, hogyaz interferon-b-tiol-reaktív poliollal reagáltatva egy poliol-maradékot kötnek helyspecifikusan és kovalensen a humán interferon-bCys17-hez, majd a kapott konjugátumot kinyerik. A fenti eljárástpolietilénglikol (PEG) maradékok kapcsolása esetén úgy végzik, hogy apolipeptidet először egy kis móltömegű heterobifunkciós vagyhomobifunkciós PEG-maradékkal reagáltatják, majd a polipeptidhezkötött kis móltömegű PEG-maradékot egy monofunkciós vagy bifunkciósPEG-maradékkal reagáltatva ez utóbbi monofunkciós vagy bifunkciós PEG-maradékot a kis móltömegű PEG-maradék szabad végéhez kötve alakítjákki a PEG-polipeptid konjugátumot. A PEG-polipeptid konjugátumokgyógyszerként alkalmazhatók. Ó
HU0300548A 1998-04-28 1999-04-28 Polyol-ifn-betha conjugates HUP0300548A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8333998P 1998-04-28 1998-04-28
PCT/US1999/009161 WO1999055377A2 (en) 1998-04-28 1999-04-28 Polyol-ifn-beta conjugates

Publications (2)

Publication Number Publication Date
HUP0300548A2 true HUP0300548A2 (hu) 2003-06-28
HUP0300548A3 HUP0300548A3 (en) 2005-07-28

Family

ID=22177687

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300548A HUP0300548A3 (en) 1998-04-28 1999-04-28 Polyol-ifn-betha conjugates

Country Status (31)

Country Link
US (3) US6638500B1 (hu)
EP (2) EP1075281B1 (hu)
JP (2) JP4574007B2 (hu)
KR (1) KR100622796B1 (hu)
CN (2) CN1187094C (hu)
AR (1) AR020070A1 (hu)
AT (2) ATE365563T1 (hu)
AU (1) AU762621B2 (hu)
BG (2) BG64694B1 (hu)
BR (1) BR9910023A (hu)
CA (2) CA2565375A1 (hu)
CY (1) CY1108022T1 (hu)
CZ (2) CZ298579B6 (hu)
DE (2) DE69920002T2 (hu)
DK (2) DK1075281T3 (hu)
EA (2) EA003789B1 (hu)
EE (1) EE05214B1 (hu)
ES (2) ES2224649T3 (hu)
HK (2) HK1038194A1 (hu)
HU (1) HUP0300548A3 (hu)
IL (1) IL139286A (hu)
NO (2) NO329749B1 (hu)
NZ (1) NZ507456A (hu)
PL (2) PL193352B1 (hu)
PT (2) PT1421956E (hu)
SI (2) SI1075281T1 (hu)
SK (2) SK286217B6 (hu)
TR (2) TR200003161T2 (hu)
TW (2) TWI232882B (hu)
UA (2) UA79430C2 (hu)
WO (1) WO1999055377A2 (hu)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
LT2599503T (lt) 1998-10-16 2017-06-26 Biogen Ma Inc. Interferono beta-1a polimero konjugatai ir jų panaudojimas
CN100480266C (zh) 1998-10-16 2009-04-22 拜奥根Idec马萨诸塞公司 干扰素-β融合蛋白及用途
AU769425B2 (en) * 1999-04-23 2004-01-29 Alza Corporation Conjugate having a cleavable linkage for use in a liposome
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7431921B2 (en) 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
TR200101086A3 (hu) * 1999-10-15 2001-08-21
WO2001048052A1 (fr) 1999-12-24 2001-07-05 Kyowa Hakko Kogyo Co., Ltd. Glycols de polyalkylene ramifies
AR027509A1 (es) 2000-01-10 2003-04-02 Maxygen Aps Conjugados g-csf
RU2278123C2 (ru) 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
DE60236796D1 (de) 2001-01-30 2010-08-05 Kyowa Hakko Kirin Co Ltd Verzweigte polyalkylenglykole
EP1234583A1 (en) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
HUP0303251A2 (hu) 2001-02-27 2003-12-29 Maxygen Aps Béta-interferon-szerű molekulák
DE60236522D1 (de) 2001-07-11 2010-07-08 Maxygen Inc G-csf konjugate
CN101700401B (zh) 2002-01-18 2013-08-14 比奥根艾迪克Ma公司 具有用于共轭生物活性化合物的部分的聚亚烷基二醇
TWI334785B (en) 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
AU2003254641A1 (en) * 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040136952A1 (en) * 2002-12-26 2004-07-15 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
KR101238517B1 (ko) * 2002-12-26 2013-02-28 마운틴 뷰 파마슈티컬즈, 인크. 생물학적 효능이 향상된 인터페론-베타의 중합체 접합체
ES2327044T3 (es) 2003-03-20 2009-10-23 Bayer Healthcare Llc Variantes de fvii o fviia.
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
EP2633866A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
JP4889505B2 (ja) 2004-02-02 2012-03-07 アンブレツクス・インコーポレイテツド 被修飾されたヒト成長ホルモンポリペプチドおよびこれらの使用
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
US7879320B2 (en) 2004-05-17 2011-02-01 Ares Trading S.A. Hydrogel interferon formulations
JP2008500995A (ja) 2004-06-01 2008-01-17 アレス トレーディング ソシエテ アノニム タンパク質安定化法
UA92146C2 (ru) 2004-06-01 2010-10-11 Эйрэс Трейдинг С.А. Стабилизированная жидкая композиция, которая содержит интерферон
WO2009100255A2 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
JP5243041B2 (ja) 2004-12-21 2013-07-24 ネクター セラピューティックス 安定化ポリマーチオール試薬
KR101224781B1 (ko) 2004-12-22 2013-01-21 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
KR20070090023A (ko) 2004-12-22 2007-09-04 암브룩스, 인코포레이티드 변형 인간 성장 호르몬
JP2008525032A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 組換えヒト成長ホルモンを発現及び精製するための方法
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
BRPI0614257A2 (pt) * 2005-08-04 2011-03-15 Nektar Therapeutics Al Corp conjugados de uma porção de g-csf e um polìmero
SG155183A1 (en) 2005-08-26 2009-09-30 Ares Trading Sa Process for the preparation of glycosylated interferon beta
KR20080050591A (ko) 2005-09-01 2008-06-09 아레스 트레이딩 에스.에이. 시신경염 치료
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
WO2007130453A2 (en) * 2006-05-02 2007-11-15 Allozyne, Inc. Non-natural amino acid substituted polypeptides
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
JP2009537605A (ja) 2006-05-24 2009-10-29 メルク セローノ ソシエテ アノニム 多発性硬化症を治療するためのクラドリビン・レジメン
KR20090013816A (ko) 2006-05-24 2009-02-05 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
EP2076533B1 (en) * 2007-05-02 2014-10-08 Ambrx, Inc. Modified interferon beta polypeptides and their uses
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
DK2234645T3 (da) 2007-12-20 2012-07-09 Merck Serono Sa Peg-interferon-beta-formuleringer
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
WO2009155102A2 (en) * 2008-05-30 2009-12-23 Barofold, Inc. Method for derivatization of proteins using hydrostatic pressure
US20110124614A1 (en) * 2008-10-25 2011-05-26 Halina Offner Methods And Compositions For The Treatment of Autoimmune Disorders
DE102009032179A1 (de) * 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
ES2365343B1 (es) 2009-11-19 2012-07-10 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de cd98 como marcador de receptividad endometrial.
JP5914363B2 (ja) 2010-02-16 2016-05-11 ノヴォ ノルディスク アー／エス 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
US20120135912A1 (en) 2010-05-10 2012-05-31 Perseid Therapeutics Llc Polypeptide inhibitors of vla4
CN102971006A (zh) 2010-07-15 2013-03-13 诺沃—诺迪斯克有限公司 稳定的因子viii变体
WO2012035050A2 (en) 2010-09-15 2012-03-22 Novo Nordisk A/S Factor viii variants having a decreased cellular uptake
CN103228290A (zh) 2011-02-18 2013-07-31 (株)斯坦帝尔 包含沉默信息调节因子1表达诱导物质的败血症或者败血性休克的预防或者治疗用组合物
US9382305B2 (en) 2011-07-01 2016-07-05 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
MY168902A (en) * 2011-10-01 2018-12-04 Glytech Inc Glycosylated polypeptide and pharmaceutical composition containing same
KR102057356B1 (ko) 2012-02-27 2019-12-18 아뮤닉스 파마슈티컬스, 인크. Ｘｔｅｎ 콘주게이트 조성물 및 그의 제조 방법
US20150030564A1 (en) 2012-02-29 2015-01-29 Toray Industries, Inc. Inhibitory agent for body cavity fluid accumulation
DK2982686T3 (en) 2013-03-29 2018-10-08 Glytech Inc POLYPEPTIDE WITH SIALYLED SUGAR CHAIN CONNECTED
WO2016013697A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 인터페론-베타 변이체의 폴리에틸렌글리콜 배합체
WO2016013911A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 페길화된 인터페론 -베타 변이체
ES2824028T3 (es) 2014-08-19 2021-05-11 Biogen Ma Inc Método de PEGilación
JP7245649B2 (ja) 2015-05-01 2023-03-24 アリスタ ファーマスーティカルス インク． 眼疾患を治療するためのアディポネクチンペプチド模倣薬（関連出願の相互参照）
WO2016205618A1 (en) * 2015-06-19 2016-12-22 Morphotek, Inc. Cys80 conjugated immunoglobulins
EP3612214A4 (en) * 2017-04-17 2021-01-20 The Regents of the University of Colorado, A Body Corporate OPTIMIZATION OF ALTERNATIVE ENZYMOTHERAPY FOR THE TREATMENT OF HOMOCYSTINURIA
US20220118050A1 (en) 2019-01-28 2022-04-21 Toray Industries, Inc. Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof
BR112021012472A2 (pt) 2019-01-28 2021-11-30 Toray Industries Forma modificada por polietileno glicol de um fator de crescimento de hepatócito ou um fragmento ativo do mesmo, e, medicamento

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
WO1987000056A1 (en) * 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5208344A (en) * 1987-07-31 1993-05-04 American Home Products Corporation Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
ES2174915T3 (es) 1993-11-10 2002-11-16 Enzon Inc Productos de conjugacion mejorados de un interferon con un polimero.
DK0690127T3 (da) 1994-03-31 1999-05-03 Amgen Inc Sammensætninger og fremgangsmåder til stimulering af megakaryocytvækst og -differentiering
DE69534318T2 (de) * 1994-05-18 2006-04-20 Nektar Therapeutics, San Carlos Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
KR0176625B1 (ko) 1996-11-05 1999-04-01 삼성전자주식회사 적외선 물체검출장치
WO1998032466A1 (en) * 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
IL133974A0 (en) * 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates

Also Published As

Publication number Publication date
EP1075281A2 (en) 2001-02-14
CZ298597B6 (cs) 2007-11-21
TR200101751T2 (tr) 2002-05-21
UA79430C2 (en) 2007-06-25
JP2002512983A (ja) 2002-05-08
CN100335503C (zh) 2007-09-05
TWI232882B (en) 2005-05-21
DK1421956T3 (da) 2007-10-01
ATE365563T1 (de) 2007-07-15
NO20005337L (no) 2000-12-28
ES2285286T3 (es) 2007-11-16
DE69920002T2 (de) 2005-09-22
US7357925B2 (en) 2008-04-15
HUP0300548A3 (en) 2005-07-28
BR9910023A (pt) 2000-12-26
HK1076115A1 (en) 2006-01-06
BG64694B1 (bg) 2005-12-30
NO20005337D0 (no) 2000-10-23
UA66857C2 (uk) 2004-06-15
CN1187094C (zh) 2005-02-02
NZ507456A (en) 2003-10-31
IL139286A (en) 2005-12-18
CY1108022T1 (el) 2013-09-04
EA200300382A1 (ru) 2005-02-24
EP1421956A1 (en) 2004-05-26
AU762621B2 (en) 2003-07-03
CA2330451A1 (en) 1999-11-04
WO1999055377A9 (en) 2000-03-02
EA005495B1 (ru) 2005-02-24
BG104871A (en) 2001-07-31
PL344490A1 (en) 2001-11-05
PT1421956E (pt) 2007-07-13
EA200001111A1 (ru) 2001-04-23
DK1075281T3 (da) 2005-01-03
AR020070A1 (es) 2002-04-10
WO1999055377A3 (en) 1999-12-29
CZ20003995A3 (en) 2001-06-13
JP2010184929A (ja) 2010-08-26
CA2565375A1 (en) 1999-11-04
US6638500B1 (en) 2003-10-28
PL193352B1 (pl) 2007-02-28
SK286654B6 (sk) 2009-03-05
SK16222000A3 (sk) 2001-04-09
AU3767499A (en) 1999-11-16
EA003789B1 (ru) 2003-10-30
CN1302209A (zh) 2001-07-04
SI1421956T1 (sl) 2007-10-31
DE69936409T2 (de) 2008-04-17
US7700314B2 (en) 2010-04-20
BG65046B1 (bg) 2007-01-31
JP4574007B2 (ja) 2010-11-04
SI1075281T1 (en) 2005-02-28
NO20100324L (no) 2000-12-28
NO332224B1 (no) 2012-07-30
TR200003161T2 (tr) 2001-01-22
CN1637020A (zh) 2005-07-13
PL196533B1 (pl) 2008-01-31
IL139286A0 (en) 2001-11-25
CZ298579B6 (cs) 2007-11-14
EE05214B1 (et) 2009-10-15
EP1075281B1 (en) 2004-09-08
EP1421956B1 (en) 2007-06-27
ES2224649T3 (es) 2005-03-01
DE69920002D1 (de) 2004-10-14
BG109291A (en) 2006-04-28
ATE275422T1 (de) 2004-09-15
HK1038194A1 (en) 2002-03-08
SK286217B6 (sk) 2008-05-06
KR100622796B1 (ko) 2006-09-13
WO1999055377A2 (en) 1999-11-04
US20070141620A1 (en) 2007-06-21
NO329749B1 (no) 2010-12-13
PT1075281E (pt) 2004-11-30
US20040043002A1 (en) 2004-03-04
TWI266800B (en) 2006-11-21
DE69936409D1 (de) 2007-08-09
KR20010071158A (ko) 2001-07-28
EE200000614A (et) 2002-04-15

Similar Documents

Publication Publication Date Title
HUP0300548A2 (hu) Poliol-ifn-béta konjugátumok
HK1154874A1 (en) Pegylated interleukin-10 -10
HK1051964A1 (en) G-csf conjugates g-csf
EP0512050A4 (en) Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
DE3786000T3 (de) Conjugate dichter Sterne.
CY1106886T1 (el) Πολυμερη προϊοντα συζευξης της neublastin και μεθοδοι χρησης αυτων
ATE451124T1 (de) Polysaccharid-peptid-konjugate
DK1180121T3 (da) Langtidsvirkende insulinotrope peptider
EP1196444B8 (en) Exendin-4 conjugates and their medical use
DE69329735T2 (de) Peptid-kohlenwasserstoff konjugate, welche t-zell immunität bewirken
BR0014652A (pt) Fabricação de conjugados de agente terapêutico-poliglutamato
DE69925830D1 (de) Peg-lhrh analog konjugate
MXPA03011094A (es) Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello.
EP2338513A3 (en) Releasable polymeric conjugates based on aliphatic biodegradable linkers
HUP0100507A2 (hu) Polietilén-glikol-GRF konjugátumok, eljárás azok helyspecifikus előállítására, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE321131T1 (de) Mutierte klasse-i-mhc-moleküle
DE69737995D1 (de) INSULINPREPARATION MIT MAnnitol
BR0308860A (pt) Fator viii modificado
HUP0101749A2 (hu) Készítmények PEG-interferon-alfa-konjugátumok védelmére és eljárás ilyen készítmények előállítására
PT557199E (pt) Conjugados de polietileno glicol hirudina processo de preparacao e uso na cura da trombose
EP0630255A4 (en) CMH CONJUGATES FOR THE TREATMENT OF AUTOIMUNITY.
YU32402A (sh) Konjugati gama interferona
AU3313789A (en) Haemophilus influenza type B oxidized polysaccharide-outer membrane protein conjugate vaccine
DK0478631T3 (da) Målsøgende midler
BR0311308A (pt) Briodina 1 modificada com imunogenicidade reduzida

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished